Incyte Corporation (INCY) Stock

Incyte Corporation is a prominent biopharmaceutical company dedicated to advancing the field of hematology/oncology, as well as inflammation and autoimmunity therapies globally. Operating in the United States, Europe, Japan, and beyond, Incyte specializes in discovering, developing, and commercializing innovative therapeutics. The company's flagship products include JAKAFI (ruxolitinib), designed for adults with intermediate or high-risk myelofibrosis, and MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), tailored for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Additionally, Incyte offers PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor addressing oncogenic drivers in various liquid and solid tumor types, and ICLUSIG, a kinase inhibitor used in treating chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The company's robust pipeline features promising candidates like axatilimab, an anti-CSF-1R monoclonal antibody aimed at chronic GVHD and other immune-mediated diseases, and parsaclisib, a PI3Kd inhibitor currently in Phase II clinical trials for follicular lymphoma and other lymphomas.

Incyte Corporation collaborates extensively through strategic partnerships with industry leaders like Novartis, Lilly, and Merus, leveraging its innovative approach to drug development. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte continues to expand its portfolio of cutting-edge therapies, with a commitment to improving outcomes for patients worldwide.